Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymosin α1 + Tislelizumab + Chemo in Resectable NSCLC
NCT06607926Not yet recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Oct 2024
- Primary completion
- Jun 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of thymosin alpha 1 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Xuanwu Hospital. Primary endpoint: Pathologic Complete Response Rate. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
thymosin alpha 1
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06607926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06607926.